{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-063740","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2026-09-28T20:47:56+00:00","discovered_at":"2026-09-28T20:48:38.376437+00:00","generated_at":"2026-10-12T13:37:21.725116+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CAMP4 Therapeutics outlines Phase 1/2 ASCEND trial for CMP-002 in SYNGAP1-related disorder at Analyst Day","bullets":["ASCEND is a Phase 1/2 randomized, double-blind, placebo-controlled MAD trial of intrathecal CMP-002 vs sham in patients aged 2 to <18 with genetically confirmed SYNGAP1-related disorder.","Trial includes three MAD cohorts with at least eight participants each, 3:1 randomization, three doses over ~3 months, and a 28-day screening plus 4-week baseline.","Sites in UK, Australia, and Argentina approved; EU under review; >11 sites across at least 9 countries; first patient dosing expected by end of 2026, topline H1 2028.","Pipeline: preclinical SHANK3 program for Phelan-McDermid Syndrome, >45,000 US patients; development candidate expected in 2027; two additional early-stage CNS haploinsufficiency programs evaluated.","Company believes CMP-002 dose levels in all three ASCEND cohorts are within expected therapeutic range based on preclinical PK/PD modeling."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-063740","json":"https://secwatch.observer/filing/0001628280-26-063740.json","markdown":"https://secwatch.observer/filing/0001628280-26-063740.md","text":"https://secwatch.observer/filing/0001628280-26-063740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026063740/0001628280-26-063740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026063740/camp-20260928.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:37:21.725116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}